Capricor Therapeutics recently joined PPMD for a community webinar on Tuesday, July 29, 2025 to discuss the current status of Capricor’s Biologics License Application (BLA) for Deramiocel (CAP-1002). We discussed the regulatory implications of a Complete Response Letter (CRL), as well as provided information about cardiomyopathy in Duchenne, the HOPE-2 and HOPE-3 (Phase 3) clinical trials, future plans to submit HOPE-3 data to the FDA, and addressed questions from the community.
Watch the recording
The post Watch: Capricor Therapeutics – Regulatory Update & Clinical Insights on Deramiocel for Duchenne Cardiomyopathy appeared first on Parent Project Muscular Dystrophy.